These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 30282634)

  • 1. Cardiovascular disease and COPD: dangerous liaisons?
    Rabe KF; Hurst JR; Suissa S
    Eur Respir Rev; 2018 Sep; 27(149):. PubMed ID: 30282634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials.
    Li C; Cheng W; Guo J; Guan W
    Int J Chron Obstruct Pulmon Dis; 2019; 14():799-808. PubMed ID: 31114181
    [No Abstract]   [Full Text] [Related]  

  • 3. Strategies for reducing the risk of cardiovascular disease in patients with chronic obstructive pulmonary disease.
    Ferri C
    High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):103-11. PubMed ID: 25655487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease.
    Brassington K; Selemidis S; Bozinovski S; Vlahos R
    Clin Sci (Lond); 2019 Apr; 133(7):885-904. PubMed ID: 30979844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities.
    Corrao S; Brunori G; Lupo U; Perticone F
    Eur Respir Rev; 2017 Sep; 26(145):. PubMed ID: 28794142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining the relationship between COPD and CVD: what are the implications for clinical practice?
    Morgan AD; Zakeri R; Quint JK
    Ther Adv Respir Dis; 2018; 12():1753465817750524. PubMed ID: 29355081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of Inhaled Long-Acting Bronchodilators With Adverse Cardiovascular Outcomes in Patients With Stable COPD: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
    Wu J; Ye Y; Li C; Zhou W; Chang R
    J Cardiovasc Pharmacol; 2019 Sep; 74(3):255-265. PubMed ID: 31306366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
    Kardos P; Worsley S; Singh D; Román-Rodríguez M; Newby DE; Müllerová H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2885-2895. PubMed ID: 27932872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment burden, clinical outcomes, and comorbidities in COPD: an examination of the utility of medication regimen complexity index in COPD.
    Negewo NA; Gibson PG; Wark PA; Simpson JL; McDonald VM
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2929-2942. PubMed ID: 29062230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease.
    Onishi K
    J Cardiol; 2017 Aug; 70(2):128-134. PubMed ID: 28325523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease.
    Oda N; Miyahara N; Ichikawa H; Tanimoto Y; Kajimoto K; Sakugawa M; Kawai H; Taniguchi A; Morichika D; Tanimoto M; Kanehiro A; Kiura K
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1119-1124. PubMed ID: 28435245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD.
    Huang YL; Lai CC; Wang YH; Wang CY; Wang JY; Wang HC; Yu CJ; Chen L
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2987-2996. PubMed ID: 29066880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnoea Syndrome and Overlap Syndrome.
    Voulgaris A; Archontogeorgis K; Steiropoulos P; Papanas N
    Curr Vasc Pharmacol; 2021; 19(3):285-300. PubMed ID: 32188387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal Dynamics of Cardiovascular Risk in Patients with Chronic Obstructive Pulmonary Disease During Stable Disease and Exacerbations: Review of the Mechanisms and Implications.
    Simons SO; Heptinstall AB; Marjenberg Z; Marshall J; Mullerova H; Rogliani P; Nordon C; Hawkins NM
    Int J Chron Obstruct Pulmon Dis; 2024; 19():2259-2271. PubMed ID: 39411574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease.
    Franssen FM; Spruit MA; Wouters EF
    Int J Chron Obstruct Pulmon Dis; 2011; 6():493-501. PubMed ID: 22069360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers.
    Chapman KR; Wise RA; Scirica BM; Bhatt DL; Daoud SZ; Lythgoe D; Gil EG
    Respir Res; 2021 Oct; 22(1):272. PubMed ID: 34686204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commencement of cardioselective beta-blockers during hospitalisation for acute exacerbations of chronic obstructive pulmonary disease.
    Neef PA; Burrell LM; McDonald CF; Irving LB; Johnson DF; Steinfort DP
    Intern Med J; 2017 Sep; 47(9):1043-1050. PubMed ID: 28608512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in outcomes between GOLD groups in patients with COPD in the TIOSPIR(®) trial.
    Dusser D; Wise RA; Dahl R; Anzueto A; Carter K; Fowler A; Calverley PM
    Int J Chron Obstruct Pulmon Dis; 2016; 11():133-45. PubMed ID: 26855568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease.
    Petta V; Perlikos F; Loukides S; Bakakos P; Chalkias A; Iacovidou N; Xanthos T; Tsekoura D; Hillas G
    Heart Fail Rev; 2017 Nov; 22(6):753-763. PubMed ID: 28840400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flavonoids and Reduction of Cardiovascular Disease (CVD) in Chronic Obstructive Pulmonary Disease (COPD).
    Russo P; Prinzi G; Lamonaca P; Cardaci V; Fini M
    Curr Med Chem; 2019; 26(39):7048-7058. PubMed ID: 29756566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.